JP2009519718A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009519718A5 JP2009519718A5 JP2008545995A JP2008545995A JP2009519718A5 JP 2009519718 A5 JP2009519718 A5 JP 2009519718A5 JP 2008545995 A JP2008545995 A JP 2008545995A JP 2008545995 A JP2008545995 A JP 2008545995A JP 2009519718 A5 JP2009519718 A5 JP 2009519718A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- hvr
- sequence
- ox40l
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 claims 14
- 210000004027 cell Anatomy 0.000 claims 10
- 239000013598 vector Substances 0.000 claims 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 208000026278 immune system disease Diseases 0.000 claims 4
- 102000040430 polynucleotide Human genes 0.000 claims 3
- 108091033319 polynucleotide Proteins 0.000 claims 3
- 239000002157 polynucleotide Substances 0.000 claims 3
- 206010012438 Dermatitis atopic Diseases 0.000 claims 2
- 101000764263 Homo sapiens Tumor necrosis factor ligand superfamily member 4 Proteins 0.000 claims 2
- 206010039085 Rhinitis allergic Diseases 0.000 claims 2
- 201000010105 allergic rhinitis Diseases 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 201000008937 atopic dermatitis Diseases 0.000 claims 2
- 210000003527 eukaryotic cell Anatomy 0.000 claims 2
- 102000051450 human TNFSF4 Human genes 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 210000001236 prokaryotic cell Anatomy 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 102000004473 OX40 Ligand Human genes 0.000 claims 1
- 108010042215 OX40 Ligand Proteins 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
- 208000024908 graft versus host disease Diseases 0.000 claims 1
- 210000004962 mammalian cell Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US75137705P | 2005-12-16 | 2005-12-16 | |
| PCT/US2006/062173 WO2007133290A2 (en) | 2005-12-16 | 2006-12-15 | Anti-ox40l antibodies and methods using same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009519718A JP2009519718A (ja) | 2009-05-21 |
| JP2009519718A5 true JP2009519718A5 (enExample) | 2011-02-10 |
Family
ID=38616368
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008545995A Withdrawn JP2009519718A (ja) | 2005-12-16 | 2006-12-15 | 抗ｏｘ４０ｌ抗体とその使用方法 |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US7812133B2 (enExample) |
| EP (1) | EP1973949A2 (enExample) |
| JP (1) | JP2009519718A (enExample) |
| KR (1) | KR20080080639A (enExample) |
| CN (1) | CN101374865A (enExample) |
| AR (1) | AR057253A1 (enExample) |
| AU (1) | AU2006343459A1 (enExample) |
| BR (1) | BRPI0621065A2 (enExample) |
| CA (1) | CA2633602A1 (enExample) |
| CR (1) | CR10069A (enExample) |
| EC (1) | ECSP088543A (enExample) |
| IL (1) | IL191820A0 (enExample) |
| MA (1) | MA30153B1 (enExample) |
| NO (1) | NO20083147L (enExample) |
| RU (1) | RU2426744C2 (enExample) |
| TW (1) | TW200732349A (enExample) |
| WO (1) | WO2007133290A2 (enExample) |
| ZA (1) | ZA200804868B (enExample) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7291331B1 (en) | 2002-09-11 | 2007-11-06 | La Jolla Institute For Allergy And Immunology | Methods of treating OX40 medicated recall immune responses |
| EP2041756B1 (en) | 2006-07-14 | 2015-05-13 | FEI Company | A multi-source plasma focused ion beam system |
| BRPI0807269A2 (pt) * | 2007-02-27 | 2014-04-29 | Genentech Inc | "anticorpo antagonista isolado, molécula de ácido nucléico isolada, vetor, célula hospedeira, composição, método de tratamento, método para tratamento, método para reduzir a severidade da asma, método para produzir um anticorpo, hibridoma, uso do anitocrpo, método para detectar ox40, kits e aparelhos médicos" |
| US20090309617A1 (en) * | 2007-08-24 | 2009-12-17 | Ye Fang | Biosensor antibody functional mapping |
| WO2009141239A1 (en) * | 2008-05-20 | 2009-11-26 | F. Hoffmann-La Roche Ag | A pharmaceutical formulation comprising an antibody against ox40l, uses thereof |
| US8518405B2 (en) * | 2009-10-08 | 2013-08-27 | The University Of North Carolina At Charlotte | Tumor specific antibodies and uses therefor |
| FI3309176T3 (fi) | 2009-12-14 | 2026-01-09 | Ablynx Nv | Immunoglobuliinin yksittäinen vaihteleva domeeni -vasta-aineita ox40l:ää vastaan, konstrukteja ja niiden terapeuttinen käyttö |
| WO2012015696A1 (en) * | 2010-07-26 | 2012-02-02 | Baylor Research Institute | Thymic stromal lymphopoietin (tslp) and ox40 ligand in cancer |
| NZ716369A (en) | 2010-08-23 | 2017-05-26 | Univ Texas | Anti-ox40 antibodies and methods of using the same |
| US9845362B2 (en) | 2010-10-08 | 2017-12-19 | The University Of North Carolina At Charlotte | Compositions comprising chimeric antigen receptors, T cells comprising the same, and methods of using the same |
| AR083847A1 (es) * | 2010-11-15 | 2013-03-27 | Novartis Ag | Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40 |
| SMT201800228T1 (it) | 2011-04-21 | 2018-07-17 | Bristol Myers Squibb Co | Polipeptidi anticorpali che antagonizzano cd40 |
| AU2012299421B2 (en) * | 2011-08-23 | 2016-02-04 | Board Of Regents, The University Of Texas System | Anti-OX40 antibodies and methods of using the same |
| ES2777939T3 (es) | 2013-09-09 | 2020-08-06 | Canimguide Therapeutics Ab | Moduladores del sistema inmunitario |
| GB201403775D0 (en) * | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
| JP2017165652A (ja) * | 2014-06-30 | 2017-09-21 | 国立大学法人東北大学 | 新規抗ヒトｏｘ４０リガンド抗体、及びこれを含む抗インフルエンザ薬 |
| CN107074951B (zh) * | 2014-08-04 | 2021-08-03 | 贝勒研究院 | 拮抗性抗-ox40l抗体及其使用方法 |
| US11554181B2 (en) | 2014-09-05 | 2023-01-17 | The University Of North Carolina At Charlotte | Tumor specific antibody conjugates and uses therefor |
| US9434785B1 (en) * | 2015-04-30 | 2016-09-06 | Kymab Limited | Anti-human OX40L antibodies and methods of treating graft versus host disease with the same |
| US9512229B2 (en) | 2015-03-03 | 2016-12-06 | Kymab Limited | Synergistic combinations of OX40L antibodies for the treatment of GVHD |
| KR20250005465A (ko) * | 2015-03-03 | 2025-01-09 | 키맵 리미티드 | 항체, 용도 및 방법 |
| US9139653B1 (en) | 2015-04-30 | 2015-09-22 | Kymab Limited | Anti-human OX40L antibodies and methods of treatment |
| US10881709B2 (en) | 2015-03-06 | 2021-01-05 | Canimguide Therapeutics Ab | Immune system modulators and compositions |
| PH12017502013B1 (en) | 2015-05-07 | 2022-07-22 | Agenus Inc | Anti-ox40 antibodies and methods of use thereof |
| TWI717432B (zh) | 2015-12-02 | 2021-02-01 | 美商艾吉納斯公司 | 抗體和使用彼之方法 |
| DE102016105069A1 (de) | 2016-03-18 | 2017-09-21 | Eberhard Karls Universität Tübingen Medizinische Fakultät | Antivirale Immuntherapie durch Membranrezeptorligation |
| EP3443984A4 (en) * | 2016-04-15 | 2019-04-10 | Pontificia Universidad Católica De Chile | PHARMACEUTICAL COMPOSITION FOR REDUCING THE SYMPTOMS AND THE SERIOUS DEGREE OF RESPIRATORY INFECTION BY human metapneumovirus (hMPV) WITH AT LEAST ONE FUNCTION OF TSLP- AND / OR TSLPR- AND / OR OX40L- AND / OR CD177-MOLECULE neutralizing agent AND PHARMACEUTICAL ACCEPTABLE ALTERNATIVE FUEL AND USE THEREOF |
| EP3471754A1 (en) | 2016-06-20 | 2019-04-24 | Kymab Limited | Anti-pd-l1 antibodies |
| US9567399B1 (en) | 2016-06-20 | 2017-02-14 | Kymab Limited | Antibodies and immunocytokines |
| KR102604433B1 (ko) | 2016-08-09 | 2023-11-24 | 키맵 리미티드 | 항-icos 항체 |
| EP3534947A1 (en) | 2016-11-03 | 2019-09-11 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses & methods |
| WO2018089628A1 (en) | 2016-11-09 | 2018-05-17 | Agenus Inc. | Anti-ox40 antibodies, anti-gitr antibodies, and methods of use thereof |
| GB201709808D0 (en) | 2017-06-20 | 2017-08-02 | Kymab Ltd | Antibodies |
| KR102634374B1 (ko) | 2017-11-24 | 2024-02-06 | 유큐(베이징) 바이오파마 코., 엘티디 | 항―ｏｘ４０ 항체 및 그의 용도 |
| EP3728314A1 (en) | 2017-12-19 | 2020-10-28 | Kymab Limited | Bispecific antibody for icos and pd-l1 |
| GB201721338D0 (en) | 2017-12-19 | 2018-01-31 | Kymab Ltd | Anti-icos Antibodies |
| GB202012331D0 (en) * | 2020-08-07 | 2020-09-23 | Petmedix Ltd | Therapeutic antibodies |
| CN114437228B (zh) * | 2020-10-30 | 2024-02-06 | 中国科学院生物物理研究所 | 一种il-2与抗体亚单位构成的双功能融合蛋白 |
| CN117440967A (zh) * | 2020-12-09 | 2024-01-23 | 怡诺安有限公司 | 抗OX40L抗体、抗OX40L/抗TNFα双特异性抗体及其用途 |
| TW202330023A (zh) * | 2021-08-10 | 2023-08-01 | 英商科馬布有限公司 | 異位性皮膚炎之治療 |
| KR20240139085A (ko) * | 2022-02-09 | 2024-09-20 | 펫메딕스 리미티드 | 치료 항체 |
| WO2025090570A1 (en) * | 2023-10-23 | 2025-05-01 | Abcellera Biologics Inc. | Anti-ox40l antibodies and methods of use |
| TW202540204A (zh) * | 2024-01-26 | 2025-10-16 | 西班牙商阿爾米雷爾有限公司 | 雙特異性分子及使用其的治療方法 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5457035A (en) * | 1993-07-23 | 1995-10-10 | Immunex Corporation | Cytokine which is a ligand for OX40 |
| US5821332A (en) | 1993-11-03 | 1998-10-13 | The Board Of Trustees Of The Leland Stanford Junior University | Receptor on the surface of activated CD4+ T-cells: ACT-4 |
| US6242566B1 (en) | 1994-02-10 | 2001-06-05 | Board Of Trustees Of The Leland Stanford Junior University | Ligand (ACT-4-L) to a receptor on the surface of activated CD4+ T-cells |
| JP3914342B2 (ja) | 1997-09-25 | 2007-05-16 | 武田薬品工業株式会社 | ｇｐ３４結合阻害物を有効成分として含有する医薬組成物 |
| CA2410188A1 (en) * | 2000-06-06 | 2001-12-13 | Idec Pharmaceutical Corporation | Non-agonistic antibodies to human gp39, compositions containing, and therapeutic use thereof |
| FR2822846B1 (fr) * | 2001-04-03 | 2004-01-23 | Technopharm | Procede de preparation et de selection d'anticorps |
| GB0123276D0 (en) | 2001-09-27 | 2001-11-21 | Imp College Innovations Ltd | Uses of agents that bind immune-system components |
| JP3926596B2 (ja) | 2001-09-28 | 2007-06-06 | 独立行政法人科学技術振興機構 | Ｏｘ４０ｌ遺伝子を導入した自己免疫疾患モデル非ヒト哺乳動物 |
| AU2002365814A1 (en) * | 2001-12-18 | 2003-07-30 | J And J Research Pty Ltd | Method of treating asthma |
| IL164376A0 (en) | 2002-04-03 | 2005-12-18 | Applied Research Systems | Ox4or binding agents, their preparation and pharmaceutical compositions containing them |
| MXPA05002219A (es) | 2002-08-28 | 2005-07-05 | Immunex Corp | Composiciones y metodos para tratar una enfermedad cardiovascular. |
| US7291331B1 (en) | 2002-09-11 | 2007-11-06 | La Jolla Institute For Allergy And Immunology | Methods of treating OX40 medicated recall immune responses |
| AU2005229009A1 (en) * | 2004-03-23 | 2005-10-13 | Amgen, Inc. | Monoclonal antibodies specific for human OX40L (CD 134L) |
| JP2006081061A (ja) * | 2004-09-13 | 2006-03-23 | Alpine Electronics Inc | 音声出力装置及び音声／映像出力装置 |
| TWI309240B (en) | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
| BRPI0807269A2 (pt) | 2007-02-27 | 2014-04-29 | Genentech Inc | "anticorpo antagonista isolado, molécula de ácido nucléico isolada, vetor, célula hospedeira, composição, método de tratamento, método para tratamento, método para reduzir a severidade da asma, método para produzir um anticorpo, hibridoma, uso do anitocrpo, método para detectar ox40, kits e aparelhos médicos" |
-
2006
- 2006-12-15 CN CNA2006800529729A patent/CN101374865A/zh active Pending
- 2006-12-15 BR BRPI0621065-1A patent/BRPI0621065A2/pt not_active IP Right Cessation
- 2006-12-15 EP EP06851330A patent/EP1973949A2/en not_active Withdrawn
- 2006-12-15 CA CA002633602A patent/CA2633602A1/en not_active Abandoned
- 2006-12-15 AR ARP060105564A patent/AR057253A1/es not_active Application Discontinuation
- 2006-12-15 WO PCT/US2006/062173 patent/WO2007133290A2/en not_active Ceased
- 2006-12-15 TW TW095147231A patent/TW200732349A/zh unknown
- 2006-12-15 RU RU2008129111/10A patent/RU2426744C2/ru not_active IP Right Cessation
- 2006-12-15 US US12/097,733 patent/US7812133B2/en active Active
- 2006-12-15 JP JP2008545995A patent/JP2009519718A/ja not_active Withdrawn
- 2006-12-15 KR KR1020087017186A patent/KR20080080639A/ko not_active Withdrawn
- 2006-12-15 ZA ZA200804868A patent/ZA200804868B/xx unknown
- 2006-12-15 AU AU2006343459A patent/AU2006343459A1/en not_active Abandoned
-
2008
- 2008-05-29 IL IL191820A patent/IL191820A0/en unknown
- 2008-06-12 CR CR10069A patent/CR10069A/es not_active Application Discontinuation
- 2008-06-13 EC EC2008008543A patent/ECSP088543A/es unknown
- 2008-07-11 MA MA31104A patent/MA30153B1/fr unknown
- 2008-07-15 NO NO20083147A patent/NO20083147L/no not_active Application Discontinuation
-
2010
- 2010-07-12 US US12/834,748 patent/US20100272738A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009519718A5 (enExample) | ||
| RU2008129111A (ru) | Антитела к ox40l и способы их применения | |
| JP2015533795A5 (enExample) | ||
| JP2011514150A5 (enExample) | ||
| JP2016512551A5 (enExample) | ||
| JP2012501669A5 (enExample) | ||
| JP2015504306A5 (enExample) | ||
| JP2009523154A5 (enExample) | ||
| JP2013198490A5 (enExample) | ||
| JP2015510510A5 (enExample) | ||
| JP2011526785A5 (enExample) | ||
| JP2014500009A5 (enExample) | ||
| JP2009525764A5 (enExample) | ||
| JP2010526028A5 (enExample) | ||
| JP2015533853A5 (enExample) | ||
| JP2012524071A5 (enExample) | ||
| JP2010534478A5 (enExample) | ||
| RU2016110891A (ru) | Антитела к fcrh5, их иммуноконъюгаты и способы их применения | |
| JP2014534242A5 (enExample) | ||
| JP2020535799A5 (enExample) | ||
| JP2018510636A5 (enExample) | ||
| JP2017502695A5 (enExample) | ||
| WO2009140348A4 (en) | Anti-il-6/il-6r antibodies and methods of use thereof | |
| RU2017128882A (ru) | Антитела к биотину и способы их применения | |
| HRP20221471T1 (hr) | Protutijela anti-fgfr3 i postupci za njihovu uporabu |